Search results for: OHE Consulting
Filter search results
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…Health Economics (OHE) published a critical evaluation of CBO’s simulation model. We concluded that the model’s assumptions about investment in new drug development were unrealistic and that CBO would underestimate…
Review of Plans for Refining Patient-Reported Outcomes Measures
19 February 2013
…see our earlier blog post. For information on other recent OHE activities in this areas, see our December blog post. For additional information, please contact Nancy Devlin at OHE. …
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…Association (DIA), OHE’s Jorge Mestre-Ferrandiz presented the results of OHE research into R&D discontinuations. The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of…
OHE responds to the 2025 UK Budget
26 November 2025
Commenting on the newly announced 2025 UK Budget, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The NHS’ long-term sustainability will only come by funding prevention—properly,…
Using Competition with Care: Comment on the Revised Regulations for the NHS
19 March 2013
OHE’s Jon Sussex has studied and written extensively on competition in the NHS. He was a member of the OHE Commission on Competition in the NHS and rapporteur of its…
19th Annual Lecture: What Constitutes Credible Evidence of Effectiveness?
4 June 2013
…19th OHE annual lecture. London: Office of Health Economics. The 2013 OHE Annual Lecture, scheduled for 16 July, will address quality in the NHS and be given by Professor Alan…
Special Issue of EJHE Examines Progress on Refinement of the EQ-5D
13 August 2013
…co-edited by OHE’s Professor Nancy Devlin and Professor Paul Krabbe of the University of Groningen/University Medical Center Groningen. Both are active members of the EuroQol Group; Nancy chairs its Executive…
How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on?
1 July 2021
…and Firth I. 2020. How Should the World Pay for a COVID-19 Vaccine? OHE Annual Lecture 2020. Office of Health Economics. Available at: https://www.ohe.org/publications/how-should-world-pay-covid-19-vaccine Chalkidou K, Towse A, Silverman R,…
Using MCDA to Assess the Value of Treatments for Rare Diseases
5 December 2013
…(OHE) and its collaborators, medicines for rare disease may be effectively valued using an innovative approach — multi-criteria decision analysis (MCDA) — that can include all relevant stakeholders, including patients’…